Suppr超能文献

3 年每半年 1 次阿苯达唑群体药物治疗对淋巴丝虫病和土源性线虫感染的效果:刚果共和国的社区研究。

Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.

机构信息

Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France.

Institut de Recherche pour le Développement, UMI233/INSERM U1175, Université de Montpellier, Montpellier, France.

出版信息

Lancet Infect Dis. 2017 Jul;17(7):763-769. doi: 10.1016/S1473-3099(17)30175-5. Epub 2017 Mar 31.

Abstract

BACKGROUND

The standard treatment strategy of mass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa, because of the risk of serious adverse events in people with high Loa loa microfilaraemia. Thus, alternative strategies are needed. We investigated one such alternative strategy for mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infections in Republic of the Congo.

METHODS

In 2012, we started a 3 year community trial of biannual mass administration of albendazole in a village in Republic of the Congo. All volunteering inhabitants aged 2 years or older were offered albendazole (400 mg) every 6 months. Infection with Wuchereria bancrofti was diagnosed with a rapid card immunochromatographic test for antigenaemia. People with antigenaemia were tested for microfilaraemia by night blood smears. Individuals were also tested for soil-transmitted helminth infections (ie, hookworm, Ascaris lumbricoides, Trichuris trichiura) with the Kato-Katz method. Assessment surveys were done at 12, 24, and 36 months. The main outcome measure was change in infection rates from baseline to year 3.

FINDINGS

Therapeutic coverage was more than 80% in all six rounds of mass administration of albendazole. Between 2012 and 2015, W bancrofti antigenaemia and microfilaraemia rates in the community fell significantly, from 17·3% (95% CI 14·7-20·0) to 4·7% (3·3-6·6; p<0·0001) and from 5·3% (3·9-7·1) to 0·3% (0·1-1·2; p<0·0001), respectively. The geometric mean microfilaria count in microfilaraemic people fell from 199·4 (120·4-330·5) per mL in 2012 to 39·1 (95% CIs not computed) per mL in 2015 (p=0·0095). Hookworm infection was undetectable after 1 year. Between 2012 and 2015, the number of A lumbricoides eggs expelled per g of faeces fell from 9844·6 (8209·0-11 480·0) to 724·4 (340·7-1114·2; p<0·0001), and of T trichiura eggs from 1107·4 (878·5-1336·3) to 366·0 (255·7-476·2; p<0·0001).

INTERPRETATION

Our findings strongly support WHO's provisional strategy of biannual mass administration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemic and ivermectin cannot be safely mass administered.

FUNDING

Bill & Melinda Gates Foundation.

摘要

背景

在中部非洲,由于伊维菌素加阿苯达唑大规模药物治疗策略对高微丝蚴血症罗阿丝虫病患者存在严重不良事件的风险,因此无法应用于淋巴丝虫病的标准治疗策略。因此,需要替代策略。我们在刚果共和国研究了一种用于消除淋巴丝虫病和土壤传播性蠕虫感染的大规模药物治疗替代策略。

方法

2012 年,我们在刚果共和国的一个村庄开始了为期 3 年的每 6 个月一次的阿苯达唑社区双年度大规模药物治疗试验。所有自愿参加的 2 岁及以上的居民每 6 个月接受一次阿苯达唑(400mg)。采用快速免疫层析卡检测抗原血症诊断班氏吴策线虫感染。通过夜间血涂片检测抗原血症患者的微丝蚴血症。还使用加藤氏法检测土壤传播性蠕虫感染(即钩虫、蛔虫、鞭虫)。在 12、24 和 36 个月进行评估调查。主要结局指标是从基线到第 3 年感染率的变化。

结果

在所有 6 轮阿苯达唑大规模药物治疗中,治疗覆盖率均超过 80%。2012 年至 2015 年,社区中班氏吴策线虫抗原血症和微丝蚴血症率显著下降,分别从 17.3%(95%CI 14.7-20.0)降至 4.7%(3.3-6.6;p<0.0001)和从 5.3%(3.9-7.1)降至 0.3%(0.1-1.2;p<0.0001)。2012 年微丝蚴血症患者的几何平均微丝蚴计数为 199.4(120.4-330.5)/mL,2015 年降至 39.1(95%CI 未计算)/mL(p=0.0095)。钩虫感染在 1 年后无法检测到。2012 年至 2015 年间,粪便中蛔虫卵排出量从每克粪便 9844.6(8209.0-11480.0)降至 724.4(340.7-1114.2;p<0.0001),鞭虫卵排出量从每克粪便 1107.4(878.5-1336.3)降至 366.0(255.7-476.2;p<0.0001)。

结论

我们的研究结果强烈支持世界卫生组织的临时性策略,即每 6 个月一次大规模使用阿苯达唑,以消除淋巴丝虫病在罗阿丝虫病流行地区,而伊维菌素不能安全地大规模使用。

资金来源

比尔和梅琳达盖茨基金会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验